Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $231K | $1.26M | $5.73M | $7.88M | $7.69M | $7.70M |
| Revenue growth | — | 445.5% | 354.7% | 37.5% | -2.4% | 0.1% |
| Operating income | -$49.2M | -$92.8M | -$90.3M | -$76.2M | -$73.0M | -$36.1M |
| Operating margin | -21290.9% | -7364.1% | -1576.6% | -967.4% | -949.9% | -469.3% |
| Net income | -$60.7M | -$98.6M | -$88.1M | -$69.2M | -$63.1M | -$33.4M |
| Net margin | -26289.2% | -7824.7% | -1537.8% | -878.6% | -820.8% | -433.7% |
| EPS (diluted) | -$28.89 | -$2.97 | -$2.36 | -$1.83 | -$33.06 | -$17.85 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$47.3M | -$57.1M | -$76.5M | -$69.5M | -$61.3M | -$39.9M |
| Capital expenditures | $3.26M | $2.34M | $1.95M | $206K | $41.0K | $72.0K |
| Free cash flow | -$50.6M | -$59.4M | -$78.5M | -$69.7M | -$61.3M | -$39.9M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $5.54M | $27.4M | $9.24M | $10.8M | $7.21M | $11.7M |
| Total assets | $46.5M | $308M | $228M | $160M | $99.6M | $56.7M |
| Total liabilities | $46.2M | $57.6M | $56.3M | $47.0M | $42.4M | $30.2M |
| Shareholders' equity | -$105M | $250M | $172M | $113M | $57.2M | $26.5M |
| Retained earnings | -$108M | -$207M | -$295M | -$364M | -$427M | -$461M |
| Shares (wtd avg diluted) | 1.99M | 33.2M | 37.4M | 37.8M | 1.91M | 1.87M |
Every figure is extracted from Bolt Biotherapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.